A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy of MK-4716 as Monotherapy and as Part of Combination Therapy in Participants With KRAS-Altered Advanced or Metastatic Solid Tumors (NCT07247110)

Researchers are looking for new ways to treat certain advanced or metastatic solid tumours. The goal of this study is to learn about the safety, tolerability, pharmacokinetics, and efficacy of MK-4716 as monotherapy and part of combination therapy in participants with KRAS-altered tumours.

Trial phase

Phase 1

Trial participation type

This trial has been designed for the Clinical Research of a Drug.

Principal investigator

Dr Mark Voskoboynik

Key inclusion data

Must demonstrate presence of Kirsten rat sarcoma viral oncogene homolog (KRAS) alteration. Has received at least 1 prior line of systemic therapy for locally advanced unresectable or metastatic disease. Has a confirmed diagnosis of metastatic non-small cell lung cancer. Must be untreated Has the ability to swallow and retain oral medication.